Caris Life Sciences, Inc.
CAI
Updated: 24/09/2026, 14:04:21
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
No summaries found.
- Share price
- $31.65
- Market cap
- $8.95B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- David Dean Halbert
- Employees
- 1,846
- IPO date
- 18/06/2025
- Beta
- 0.67798007
- Last dividend
- $0.00
- Day range
- $31.10 – $32.88
- 52-week range
- $14.19 – $33.66
- 1-day performance
- 0.57%
- 1-year performance
- 123.04%
- Current drawdown (1Y)
- -5.96%
- CIK
- 0002019410
- CUSIP
- 142152107
- ISIN
- US1421521071
- Created
- 07/12/2025, 03:10:40
- Last update
- 24/09/2026, 14:04:21
Track Caris Life Sciences, Inc. with an AI analyst
See which prediction-market events move CAI, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 17:48:32
Caris Life Sciences Announces Share Repurchase Program
PRNewsWire • STOCK • 08/06/2026, 10:30:00
Caris Life Sciences (NASDAQ:CAI): AI-Driven Healthcare and Capital Efficiency Analysis
Market Data • Market Data • 28/05/2026, 22:00:10
Capitan Investment Ltd. Announces Adoption of Semi-Annual Reporting
Newsfile Corp • STOCK • 28/05/2026, 16:11:00
Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing
PRNewsWire • STOCK • 26/05/2026, 10:30:00
Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%
MarketBeat • STOCK • 13/05/2026, 07:06:51
Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/05/2026, 17:40:51
Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels
PRNewsWire • STOCK • 11/05/2026, 14:15:00
Caris Life Sciences (NASDAQ:CAI) Faces Market Pressure Amid Strong Revenue Growth
Market Data • Market Data • 08/05/2026, 23:09:11
Caris Life Sciences, Inc. (CAI) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 08/05/2026, 12:41:17
Caris Life Sciences (NASDAQ:CAI) Reports Strong Q1 Earnings and Robust Financial Health
Market Data • Market Data • 08/05/2026, 04:00:11
Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies
PRNewsWire • STOCK • 04/05/2026, 10:30:00